Business Wire

CORRECTING and REPLACING PHOTO Zynga Celebrates Bugatti’s 110th Anniversary with Special CSR Racing 2 Event Series

4.12.2019 20:27:00 EET | Business Wire | Press release

Share

Please replace the photo with the accompanying corrected photo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005025/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Zynga Celebrates Bugatti’s 110th Anniversary with Special CSR Racing 2 Event Series (Photo: Business Wire)

The release reads:

ZYNGA CELEBRATES BUGATTI’S 110TH ANNIVERSARY WITH SPECIAL CSR RACING 2 EVENT SERIES

Players Can Race and Collect Exclusive Bugatti-Engineered Hyper Sports Cars in Game

Today, Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, is launching an event series in partnership with the hyper sports car manufacturer Bugatti in the hit mobile drag racing game, CSR Racing 2 (CSR2). The event series, which celebrates Bugatti’s 110th anniversary, will give players the opportunity to collect and compete with the world’s most powerful and exclusive hyper sports cars in CSR2.

“Bugatti is one of the most iconic and revered car manufacturers in the world, and we are truly honored to celebrate such an important milestone with them,” said Julian Widdows, Vice President of CSR2. “Our team worked tirelessly to make sure everything from the cars’ sleek forms to their powerful engines is authentically represented in the game. This is the closest an aficionado can come to owning a Bugatti without actually buying one.”

The series showcases 24 different Bugatti cars, three of which are available exclusively in CSR2. Players can view the cars in augmented reality, giving them the experience of sitting in the driver’s seats of the most desirable hyper sports cars ever designed. The integration has seven different events over an eight-week period, and will be highlighted in a continued beta version of CSR2’s new player-versus-player feature, Showdown.

CSR2 Bugatti Exclusives:

  • Chiron Super Sport 300: the first series production car to break the magical 300 miles per hour barrier
  • La Voiture Noire: a one-off one grand tourisme masterpiece
  • Centodieci: the newly released homage to the original modern-day super sports car, EB110

“Interactive entertainment is a main driver for today’s young generation’s enthusiasm for cars and a great way to stay in touch with fans around the world,” said Bugatti President, Stephan Winkelmann. “We are very excited that through this partnership, our enthusiasts have the opportunity to experience all of our latest exclusive Bugatti hyper sports cars in CSR2.”

Every aspect of the 24 Bugatti cars, from the grills to the paint color, dashboard finish and stitching, has been meticulously recreated in CSR2 to mirror the real hyper sports cars. Players can explore the cars by tapping special points to trigger handcrafted, bespoke animations, allowing them to open doors, pop the hoods, inspect the engine bays, extend the spoilers and more.

CSR2 is available to download for free on the App Store as well as the Google Play Store. For more information about CSR2, visit the game’s community channels on Facebook, Twitter, Instagram, and YouTube.

Editor’s Note - To view the supporting assets for CSR Racing 2 (CSR2), please click here: https://app.box.com/s/56junq0iv8ibm2dx0mqfo8hpkd7qlk64

About Zynga Inc.

Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing™, Empires & Puzzles™, Merge Dragons!™, Words With Friends™ and Zynga Poker™. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter and Facebook.

About Bugatti

Bugatti Automobiles S.A.S. manufactures the world's most powerful, fastest, most exclusive and luxurious production hyper sports car. Since its foundation in 1909, the French luxury brand has been based on and off in Molsheim, Alsace. The Veyron was made there between 2005 and 2015, the first modern-day hyper sports car, of which 450 vehicles were built by hand. Since autumn 2016, the staff in Molsheim have been producing the Chiron1 models.

With an output of 1,500 hp, which has never before been achieved by production vehicles, a torque of 1,600 newton metres at 2,000 to 6,000 rpm and numerous technical innovations, the Chiron1 has been setting new standards in automotive engineering ever since.

In 2017, Bugatti delivered 70 vehicles to customers, by 2018 this had increased to 76. More than 80 vehicles are set to be delivered to customers in 2019. Bugatti has announced the construction of 500 models – currently only 100 Chiron can be ordered. Production of the Divo2, a vehicle optimised for lateral acceleration, will follow soon.

Bugatti has been part of the Volkswagen Group since 1998 and employs more than 300 people. The majority of these work in Molsheim in Alsace. With 37 dealers and service partners in 18 countries in Europe, North America, the Middle East and Asia-Pacific, Bugatti is a global player.

1 Fuel consumption, l/100km: urban 35.2 / extra-urban 15.2 / combined 22.5; combined CO2 emissions, g/km: 516; efficiency class: G

2 Fuel consumption, l/100km: not subject to Directive 1999/94/EC as overall type approval is currently not yet available

Forward Looking Statement

This press release contains forward-looking statements, relating to, among other things, the release of future CSR Racing 2 game features and events. Forward-looking statements often include words such as "outlook," "projected," “planned,” "intends," "will," "anticipate," "believe," "target," "expect," and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions are or will be described in greater detail in our public filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained by visiting our Investor Relations web site at http://investor.zynga.com or the SEC's web site at www.sec.gov

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Zynga Media Contact:
Kenny Johnston
kjohnston@zynga.com | (602) 999-1890

Or

Bugatti Automobiles S.A.S. Contact:
Tim Bravo
Head of Communications
Mobile: +33 640 151969
Email: tim.bravo@bugatti.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye